Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.
Saved in:
| Title: | Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden. |
|---|---|
| Authors: | Shemesh CS; Clinical Pharmacology, Genentech Inc., South San Francisco, CA, USA., Chan P; Clinical Pharmacology, Genentech Inc., South San Francisco, CA, USA., Legrand FA; Clinical Science, Genentech Inc., South San Francisco, CA, USA., Shames DS; Biomarkers, Genentech Inc., South San Francisco, CA, USA., Das Thakur M; Biomarkers, Genentech Inc., South San Francisco, CA, USA., Shi J; Safety Science, F. Hoffmann-La Roche Ltd., Shanghai, China., Bailey L; Safety Science, Roche Products Ltd., Welwyn Garden City, United Kingdom., Vadhavkar S; Clinical Pharmacology, Genentech Inc., South San Francisco, CA, USA., He X; Biometrics, Genentech Inc., South San Francisco, CA, USA., Zhang W; Biometrics, Genentech Inc., South San Francisco, CA, USA., Bruno R; Clinical Pharmacology, Genentech-Roche, Marseille, France. |
| Source: | Pharmacology research & perspectives [Pharmacol Res Perspect] 2020 Dec; Vol. 8 (6), pp. e00685. |
| Publication Type: | Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 101626369 Publication Model: Print Cited Medium: Internet ISSN: 2052-1707 (Electronic) Linking ISSN: 20521707 NLM ISO Abbreviation: Pharmacol Res Perspect Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
